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Carcinoembryonic Antigen Level Can be Overestimated in 
Metabolic Syndrome
Carcinoembryonic antigen (CEA) levels can be affected by many factors and metabolic 
syndrome is also a candidate. This study examined the relationship between CEA levels and 
metabolic syndrome using the data of 32,897 healthy Koreans. Fecal occult blood tests 
were also performed. Subjects with colorectal carcinoma were excluded. Subjects were 
classified by their smoking status, metabolic syndrome and its components. Prevalence of 
metabolic syndrome and its all components showed a significant increase according to the 
quartile of serum CEA concentration (P < 0.001). Increased numbers of metabolic 
syndrome components showed a positive association with CEA levels (P-trend < 0.001). 
The odds ratios for the highest CEA quartile vs the lowest serum CEA quartile significantly 
increased in the presence of metabolic syndrome and its components. After adjusting for 
age, gender and smoking status, metabolic syndrome, low high density lipoprotein 
cholesterol and elevated blood pressure had higher odds ratios (OR) of the highest CEA 
quartile compared with the lowest serum CEA quartile (OR = 1.125, 95% CI = 1.030 to 
1.222, P = 0.009; OR = 1.296, 95% CI = 1.195 to 1.405, P < 0.001; OR = 1.334, 95% CI = 
1.229 to 1.448, P < 0.001, respectively). These results indicate that metabolic syndrome is 
associated with CEA value, which may lead to a misunderstanding of the CEA levels. 
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INTRODUCTION
Carcinoembryonic antigen (CEA) is overexpressed in adenocar-
cinomas in the colon and other organs including the pancreas, 
lung, prostate, urinary bladder, ovary, and breast. Therefore, it 
is used globally as a serological marker of malignant tumors. 
Serum CEA levels may also be affected by some nonmalignant 
conditions such as ageing, chronic renal failure, hypothyroid-
ism, cigarette smoking, chronic obstructive pulmonary disease, 
and obesity (1-5).
  Metabolic syndrome is a combination of several metabolic 
and physiological abnormalities in the same individual, includ-
ing obesity, insulin resistance, glucose intolerance, hyperten-
sion, and dyslipidemia, and is associated with high morbidity 
and mortality (6, 7). Metabolic syndrome is a common metabol-
ic disorder that results from the increasing prevalence of obesi-
ty, and which is an emerging clinical problem of enormous pro-
portions, particularly in light of the rising prevalence of obesity 
(6, 7). Metabolic syndrome has also been identified as a causal 
risk factor for cardiovascular disease and several forms of can-
cer, such as cancers of the breast, pancreas, and colon (8-10). 
One recent study reported that obesity was associated with de-
creased CEA levels (11), which may lead to loss of sensitivity and 
diagnostic accuracy in the CEA test. Thus, interrelationships be-
tween CEA levels and individual component of metabolic syn-
drome may exist partly because of their associations with obe-
sity. However, the relationship between an individual and the 
combined components of metabolic syndrome and the level of 
CEA are currently unknown. 
  The present study was grounded in the hypothesis that com-
ponents of metabolic syndrome may profoundly affect CEA lev-
els, and should be considered as a factor associated with inap-
propriately increased or decreased CEA levels. The aim of this 
study was to examine whether CEA levels were associated with 
metabolic syndrome in Koreans. 
MATERIALS AND METHODS
Study data
From January 2007 to May 2009, the data of 39,906 Koreans aged 
10-86 yr, who visited the Health Promotion Center, Ajou Univer-
sity Hospital, Suwon, Gyeonggi-do, Republic of Korea, were re-
viewed for inclusion in the study. Medical history, demograph-
ics, anthropometric, and laboratory data were collected. Data Kim K-N, et al.  •  Metabolic Syndrome and Serum CEA 
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on cigarette smoking were collected by a self-reported question-
naire. Subjects who, at the time of the survey, had quit smoking 
for ≤ 1 month or > 1 month were considered to be, respectively, 
current and former smokers. Those without a smoking history 
were considered to be never smokers. Of the initial 39,906 sub-
jects, 6,619 (16.5%) were excluded because of absent data for any 
component of metabolic syndrome, serum CEA levels, or smok-
ing history. Subjects with prior diagnosis of colorectal cancer 
(CRC), gastric cancer, pancreatic cancer, lung cancer, or breast 
cancer, which are known to affect serum CEA levels, were ex-
cluded. Fecal occult blood tests were performed in all subjects. 
Of these with positive occult blood tests (n = 597), seven subjects 
with CRC in additional colonoscopic findings were excluded. 
Thus, a total of 32,897 healthy Korean (13,845 females, 19,052 
males) were included in the final analyses. 
Measurements
Serum CEA was measured using a commercially available im-
munometric chemiluminescent assay kit (Bayer Medical, Tokyo, 
Japan) with an interassay coefficient of variation ranging between 
2.0% and 3.5%. Blood pressure (BP) was measured using a stan-
dard mercury manometer with the participant in a sitting posi-
tion for 5 min prior to measurement; the average of two mea-
surements was recorded. Circumferential measurements of the 
waist at the umbilicus were performed with the patients in a 
standing position. Fasting blood specimens were used for mea-
suring lipids, glucose, and CEA. Metabolic syndrome was de-
fined as three or more of the following criteria, according to the 
American Heart Association/Updated National Cholesterol Ed-
ucation Program Third Adult Treatment Panel guidelines (NCEP 
ATP III): waist measurement ≥ 102 cm for males and ≥ 88 cm for 
females, triglyceride level ≥ 150 mg/dL, high-density lipoprotein 
cholesterol (HDL cholesterol) < 40 mg/dL for males and < 50 mg/ 
dL for females, BP ≥ 130/85 mmHg or the use of BP medications, 
and fasting glucose level ≥ 100 mg/dL or undergoing treatment 
for hyperglycemia (12). Abdominal girth cut-off to determine 
waist circumference (WC) was defined according to central obe-
sity in Koreans (≥ 90 cm for males and ≥ 85 cm for females) (13). 
Subjects were grouped by smoking status, the sum of individual 
metabolic components (0-5), and the presence or absence of 
metabolic syndrome (yes or no). Body mass index (BMI) was 
calculated as weight (kg) divided by height squared (m
2).
Statistics
Analysis of variance (ANOVA) was used to compare baseline 
characteristics and the prevalence of metabolic syndrome, met-
abolic syndrome components according to the quartile of serum 
CEA concentration. We examined the mean serum CEA concen-
tration according to the number of metabolic syndrome com-
ponents. ANOVA Trend analysis using polynomial contrasts was 
adapted to perform tests for trend. We also investigated to deter-
mine which variables were significant contributors to the serum 
CEA level in the adjusted state for each variable through ordinal 
logistic regression analyses using the quartile of serum CEA con-
centration. 
  Results of group data are expressed as mean ± standard devi-
ation (SD). All statistical analyses were performed using SPSS 
13.0 software (SPSS, Chicago, IL, USA). P values < 0.05 were con-
sidered statistically significant. 
Ethics statement
All participants agreed to the use of their health check-up results. 
The institutional review board of Ajou University Hospital ap-
proved this study (AJIRB-MED-OBS-10-415). Informed consent 
was waived by the board. 
Table 1. Baseline characteristics of study subjects according to the quartile of serum CEA concentration
Variables* 1st quartile (n = 8,328)  
(CEA 0.35 ng/mL)
†
2nd quartile (n = 8,301)  
(CEA 0.72 ng/mL)
†
3rd quartile (n = 8,105)  
(CEA 1.44 ng/mL)
†
4th quartile (n = 8,163)  
(CEA 2.35 ng/mL)
†
Age (yr) 41.73 ± 8.90 44.38 ± 9.72 45.88 ± 9.97   48.71 ± 10.43
BMI (kg/m
2)  23.36 ± 3.19 23.78 ± 3.16 23.97 ± 3.09 24.09 ± 3.02
Men (No., %)  3,245 (40.4) 4,145 (52) 5,449 (63.5) 6,501 (75.6)
WC (cm)  81.92 ± 8.34 83.15 ± 8.16 83.71 ± 8.15 84.34 ± 8.07
TG (mg/dL) 103.47 ± 76.06 113.12 ± 82.95 122.08 ± 87.08   134.90 ± 101.59
HDLC (mg/dL)    53.89 ± 12.89   53.31 ± 12.68   52.48 ± 12.78   51.97 ± 13.15
SBP (mm Hg)  116.31 ± 14.23 118.34 ± 14.65 119.71 ± 14.75 121.22 ± 15.05
DBP (mm Hg)   75.42 ± 11.24   77.14 ± 11.17   78.55 ± 11.29   79.70 ± 11.17
FBS (mg/dL)   92.32 ± 12.23   94.44 ± 14.59   96.27 ± 17.83 101.78 ± 29.29
TC (mg/dL)  180.95 ± 32.30 185.66 ± 33.25 188.12 ± 33.39 191.62 ± 33.92
Smoking status
   Non (No., %) 5,904 (73.5)    5,033 (63.1) 4,095 (50.5) 2,898 (35.5)
   Former (No., %) 1,214 (15.1)    1,438 (18.0) 1,689 (20.8) 1,542 (18.9)
   Current (No., %)    910 (11.3)    1,501 (18.8) 2,321 (26.6) 3,723 (45.6)
Data were shown as mean ± SD. *P < 0.001, All values show statistical significance in the comparisons of variables according to the quartile of serum CEA concentration; 
†Data are presented as a median value. BMI, body mass index; WC, waist circumference; TG, triglyceride; HDLC, high-density lipoprotein cholesterol; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; FBS, fasting blood sugar; TC, total cholesterol; Non, non-smoker; Former, former smoker; Current, current smoker.Kim K-N, et al.  •  Metabolic Syndrome and Serum CEA 
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RESULTS
The baseline characteristics of 32,897 subjects according to the 
quartile of serum CEA concentration are summarized in Table 
1. The median (range) of the first to fourth quartiles of CEA lev-
els was 0.35 (0.22-0.48), 0.72 (0.62-0.82), 1.44 (1.01-1.29), and 
2.35 (2.0-4.94) ng/mL, respectively. Compared to subjects with 
the lowest serum CEA quartile, those with higher serum CEA 
quartile were older and more likely to be male and current smok-
er. Anthropometric measurements and biochemical measure-
ments were significantly different between the serum CEA quar-
tile (P < 0.001). In case of triglycerides, this difference between 
the serum CEA quartile remained statistically significant after 
log-transformation.
  Prevalence of metabolic syndrome and its all components 
showed a significant increase according to the quartile of serum 
CEA concentration (P < 0.001; Fig. 1). We then assessed whether 
CEA levels were affected by the number of metabolic syndrome 
Fig. 1. Prevalence of metabolic syndrome and its components according to the quartile of serum CEA concentration. Prevalence of metabolic syndrome and its all components 
show a significant increase according to the quartile of serum CEA concentration (P < 0.001). WC, waist circumference; HDLC, high-density lipoprotein cholesterol; BP, blood 
pressure; IFG, impaired fasting glucose. Q1, 1st quartile; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th quartile.
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Fig. 2. The relationship between carcinoembryonic antigen (CEA) level and the sum 
of metabolic syndrome components. Vertical bar indicates 95% confidence interval. 
White circle indicates mean. Lower and upper bar indicates 95% confidence interval 
(P-trend < 0.001).  
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Table 2. Logistic regression analysis of the metabolic syndrome and its components as independent variables and CEA quartiles as a dependent variable
Odds Ratio (95% CI; P  value)
Q2 Q3 Q4
Model 1
   MS
   Increased WC
   Elevated triglycerides
   Low HDLC
   Elevated BP
   IFG
1.373 (1.261-1.495; < 0.001)
1.157 (1.080-1.240; < 0.001)
1.280 (1.183-1.384; < 0.001)
1.128 (1.049-1.215; 0.001)
1.334 (1.247-1.428; < 0.001)
1.383 (1.279-1.495; < 0.001)
1.654 (1.523-1.796; < 0.001)
1.199 (1.119-1.284; < 0.001)
1.608 (1.490-1.735; < 0.001)
1.179 (1.097-1.268; < 0.001)
1.647 (1.541-1.761; < 0.001)
1.681 (1.558-1.813; < 0.001)
2.089 (1.927-2.264; < 0.001)
1.243 (1.161-1.331; < 0.001)
2.092 (1.943-2.254; < 0.001)
1.233 (1.146-1.326; < 0.001)
2.508 (1.926-2.198; < 0.001)
2.388 (2.219-2.571; < 0.001)
Model 2
   MS
   Increased WC
   Elevated triglycerides
   Low HDLC
   Elevated BP
   IFG
1.056 (0.967-1.154; 0.226)
1.026 (0.955-1.101; 0.484)
0.970 (0.893-1.054; 0.472)
1.149 (1.067-1.238; < 0.001)
1.018 (0.946-1.095; 0.639)
1.083 (0.998-1.176; 0.056)
1.081 (0.990-1.179; 0.082)
1.004 (0.935-1.079; 0.906)
0.987 (0.909-1.071; 0.753)
1.196 (1.108-1.290; < 0.001)
1.067 (0.992-1.148; 0.081)
1.123 (1.035-1.217; 0.005)
1.125 (1.030-1.222; 0.009)
0.970 (0.900-1.046; 0.435)
1.017 (0.936-1.104; 0.697)
1.296 (1.195-1.405; < 0.001)
1.114 (1.033-1.201; 0.005)
1.334 (1.229-1.448; < 0.001)
Reference group; no metabolic syndrome and normal metabolic components. Model 1, before adjustment; Model 2, after adjustment for age, sex, and smoking status. MS, 
presence of metabolic syndrome; BMI, body mass index; WC, waist circumference; HDLC, high-density lipoprotein cholesterol; BP, blood pressure; IFG, impaired fasting 
glucose; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th quartile. CI, confidence interval.Kim K-N, et al.  •  Metabolic Syndrome and Serum CEA 
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components. Increasing sums of metabolic syndrome compo-
nents were significantly associated with linear increasing trends 
in CEA levels (P-trend < 0.001) (Fig. 2). 
  Table 2 reports the ordinal logistic regression models used to 
evaluate the association between metabolic syndrome, each 
components and serum CEA levels. The odds ratios (OR) for 
the highest CEA quartile for the lowest serum CEA quartile were 
significant in the presence of metabolic syndrome and its com-
ponents. After adjusting for age, gender and smoking status, met-
abolic syndrome, low HDLC and elevated BP had higher odds of 
the highest CEA quartile compared with the lowest serum CEA 
quartile (OR = 1.125, 95% confidence interval [CI] = 1.030 to 1.222, 
P = 0.009; OR = 1.296, 95% CI = 1.195 to 1.405, P < 0.001; OR = 
1.334, 95% CI = 1.229 to 1.448, P < 0.001, respectively). Former 
and current smokers also displayed higher odds of the highest 
CEA quartile compared with the lowest serum CEA quartile; 
the association was statistically significant (P < 0.05; data not 
shown).
 
DISCUSSION
The present data demonstrate that the sum of metabolic syn-
drome components is positively associated with serum CEA 
levels, and metabolic syndrome and its components have high-
er odds ratios of the highest CEA quartile compared with the 
lowest serum CEA quartile. In particular, serum CEA levels were 
found to be inversely significant to HDLC. This association re-
mained statistically significant even after adjusting for age, BMI, 
and smoking status.
  Over the past several years, the prevalence of metabolic syn-
drome has sharply increased worldwide (7, 14, 15), and is asso-
ciated with the international epidemic of diabetes and obesity 
(6, 7, 14). Metabolic syndrome is associated with the increased 
risks of cardiovascular disease and various cancers, including 
colorectal carcinoma (CRC) (8-10, 16). As well, individual com-
ponents of metabolic syndrome have been linked to an increased 
risk of CRC (9, 17). Recent studies have provided information 
concerning the association between CRC incidence and the num-
ber of metabolic syndrome components, especially BMI, lipid 
levels, plasma glucose, and glycosylated hemoglobin (HbA1c) 
(18, 19). One study demonstrated that there was a dose-response 
association between CRC incidence and the number of meta-
bolic syndrome components present at baseline (P for trend = 
0.006) after multivariate adjustment (18). Thus, it is possible that 
metabolic syndrome itself could confer an increased risk of CRC. 
  Serum CEA was elevated in subjects with CRC as well as gas-
tric carcinoma, pancreatic carcinoma, lung carcinoma and breast 
carcinoma. CEA levels may also be raised in some non-neoplas-
tic diseases like chronic inflammatory conditions. A recent study 
documented the association between serum CEA and carotid 
atherosclerosis, independent of atherogenic risk factors and 
markers of inflammation (20). Another study reported that in-
creased CEA concentrations are an independent determinant 
for acute coronary syndrome (OR = 3.1, 95% CI = 1.2-7.9, P < 0.05) 
after correction for other significant risk factors (21). Taken to-
gether, the data indicate the plausibility that serum CEA may be 
associated with metabolic syndrome and increased insulin re-
sistance. Presently, the serum CEA level was also associated with 
components of the metabolic syndrome and the syndrome itself.
  What is the possible underlying mechanism to explain the 
observed link between metabolic syndrome, individual compo-
nents, and serum CEA? First, insulin has been shown to affect 
growth of normal and neoplastic epithelial cells, and to have mi-
togenic actions in vitro and in experimental models, either di-
rectly or indirectly through insulin-like growth factor-1 (IGF-1) 
(18). One study reported that an antisense IGF-I gene that blocks 
the corresponding IGF sequences may be the reason for the de-
crease of CEA (22). Thus, insulin resistance may be associated 
with the increase of CEA. Second, visceral adiposity is positively 
correlated with clinical manifestations associated with insulin 
resistance, including type 2 diabetes and dyslipidemia. Visceral 
fat releases greater quantities of adipokines, which are related 
to either metabolic syndrome or cancer (23), and they may serve 
as a link between metabolic syndrome, individual components, 
and serum CEA. Third, while the relationship between high BP, 
low HDL cholesterol, and serum CEA is still unknown, increased 
risk of CRC and chronic inflammation has been linked with high 
BP (9, 17, 18, 24) and inversely associated with HDL cholesterol 
concentration and established cardiovascular disease (25). CEA 
is a tumor-associated antigen of gastrointestinal cancer that is 
associated with chronic inflammatory conditions. This may ex-
plain the finding of an association between high BP, low HDL 
cholesterol, and serum CEA. 
  The present study also has revealed a positive association of 
former/current smoking status with serum CEA levels, com-
pared with never smoking. This finding is supported by previ-
ous observations that serum CEA levels were significantly high-
er in smokers and that cigarette smoking is associated with in-
creased serum CEA levels in a dose- and duration-dependent 
manner, with the association being more prominent in current 
smokers than in former smokers (20).
  There are some limitations with this study. First, because the 
study was cross-sectional, we cannot determine whether there 
was a causal or resultant relationship between the individual and 
the combined components of metabolic syndrome and the ele-
vation of serum CEA. Second, it is not clear whether the analy-
sis of this restricted patient group introduced a selection bias, 
and these findings may or may not reflect the situation in the 
overall population. Third, serum CEA is known to be elevated 
in other nonmalignant conditions, such as hypothyroidism and 
end-stage lung diseases. We did not include these disorders as 
confounding variables, because their prevalence is considered Kim K-N, et al.  •  Metabolic Syndrome and Serum CEA 
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to be very low among the study population.
  In conclusion, the present study reports a positive association 
between former or current smoking status, metabolic syndrome, 
some components of metabolic syndrome and elevation of se-
rum CEA, and demonstrates that serum CEA levels are inversely 
significant by HDL cholesterol levels. Thus, metabolic syndrome 
might be a factor that is associated with CEA levels, which may 
lead to a misunderstanding of the CEA levels. 
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Carcinoembryonic antigen (CEA) levels can be affected by various factors including metabolic syndrome. This study examined the 
relationship between CEA levels and metabolic syndrome using the data of 32,897 healthy Koreans. Prevalence of metabolic 
syndrome and its all components showed a significant increase according to the quartile of serum CEA concentration. Metabolic 
syndrome, low high density lipoprotein cholesterol and elevated blood pressure were found to be significantly associated with the 
highest CEA quartile compared with the lowest serum CEA quartile. These results indicate that metabolic syndrome is associated 
with CEA levels.